AN OPEN-LABEL, SINGLE-TREATMENT, SINGLE-PERIOD, SINGLE DOSE, CLINICAL PHASE 1 STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF TYPHOID (Vi CAPSULAR POLYSACCHARIDE) TETANUS TOXOID CONJUGATE VACCINE OF M/s CADILA HEALTHCARE LTD., INDIA IN HEALTHY, ADULT, MALE, HUMAN SUBJECTS. - TYTTSD 1001
Latest Information Update: 12 Nov 2019
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary)
- Indications Tetanus; Typhoid
- Focus Adverse reactions
- Sponsors Cadila Healthcare
- 07 Sep 2016 New trial record